Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern

Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern Publisher Pubmed

Salehi M¹ ; Hosseini H² ; Jamshidi HR³ ; Jalili H⁴ ; Tabarsi P⁵ ; Mohraz M⁶ ; Karimi H⁷ ; Lotfinia M⁸ ; Aalizadeh R⁹ ; Mohammadi M¹⁰ ; Ramazi S¹¹ ; Abdoli A^{7, 12}

Show Affiliations

1. Infectious Diseases Department, Tehran University of Medical Sciences, Tehran, Iran
2. Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Pharmacology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4. Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran
5. Department of Infectious Disease, Clinical Tuberculosis and Epidemiology Research Center, Shahid Beheshti University of Medical Sciences Tehran, Iran
6. Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences Tehran, Iran
7. Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
8. Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran
9. Department of Biochemistry, Faculty of Biological Science, Tarbiat Modares University, Tehran, Iran
10. Department of Microbiology and Immunology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
11. Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
12. Amirabad Virology Laboratory, Vaccine Unit, Tehran, Iran

Source: Clinical Microbiology and Infection Published:2022

Abstract

Objectives: The BIV1-CovIran vaccine is highly effective against COVID-19. The neutralizing potency of all SARS-CoV-2 vaccines seems to be decreased against variants of concern. We assessed the sensitivity of the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants to neutralizing antibodies (NAbs) present in sera from individuals who had received the BIV1-CovIran candidate vaccine compared with an original Wuhan-related strain. Methods: The ability of vaccine serum to neutralize the variants was measured using the conventional virus neutralization test. The correlation of spike (S) protein antibody and anti-receptor binding domain with neutralizing activity was investigated. Results: The current study demonstrated that 29 of 32 (90.6%; 95% CI: 75.0–98.0) of the vaccinees developed NAbs against a Wuhan-related strain. It is noteworthy that 28 (87.50%) and 24 of 32 (75%) of the recipients were able to produce NAbs against Alpha, Beta, and Delta variants, respectively. Serum virus-neutralizing titres for different SARS-CoV-2 strains were weakly correlated with anti–receptor binding domain antibodies (Spearman r = 36-42, p < 0.05), but not S-binding antibodies (p > 0.05). Discussion: Although there was a reduction in neutralization titres against the Alpha, Beta, and Delta variants compared with the Wuhan strain, BIV1-CovIran still exhibited potent neutralizing activity against the SARS-CoV-2 variants of concern. © 2022 European Society of Clinical Microbiology and Infectious Diseases

2. A Comparison Between Sars-Cov-1 and Sars-Cov2: An Update on Current Covid-19 Vaccines, DARU# Journal of Pharmaceutical Sciences (2022)

3. Covid-19 Vaccination Challenges: A Mini-Review, Human Vaccines and Immunotherapeutics (2022)

4. Sars-Cov-2 Omicron (Ba.4, Ba.5) Variant: Lessons Learned From a New Variant During the Covid-19 Pandemic, Health Science Reports (2024)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (1)

Seyed Rohollah Miri (1)

Style	Citing Format
MLA	Salehi M, et al.. "Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern." Clinical Microbiology and Infection, vol. 28, no. 6, 2022, pp. 882.e1-882.e7.
APA	Salehi M, Hosseini H, Jamshidi HR, Jalili H, Tabarsi P, Mohraz M, Karimi H, Lotfinia M, Aalizadeh R, Mohammadi M, Ramazi S, Abdoli A (2022). Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern. Clinical Microbiology and Infection, 28(6), 882.e1-882.e7.
Chicago	Salehi M, Hosseini H, Jamshidi HR, Jalili H, Tabarsi P, Mohraz M, Karimi H, et al.. "Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern." Clinical Microbiology and Infection 28, no. 6 (2022): 882.e1-882.e7.
Harvard	Salehi M et al. (2022) 'Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern', Clinical Microbiology and Infection, 28(6), pp. 882.e1-882.e7.
Vancouver	Salehi M, Hosseini H, Jamshidi HR, Jalili H, Tabarsi P, Mohraz M, et al.. Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern. Clinical Microbiology and Infection. 2022;28(6):882.e1-882.e7.
BibTex	@article{ author = {Salehi M and Hosseini H and Jamshidi HR and Jalili H and Tabarsi P and Mohraz M and Karimi H and Lotfinia M and Aalizadeh R and Mohammadi M and Ramazi S and Abdoli A}, title = {Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern}, journal = {Clinical Microbiology and Infection}, volume = {28}, number = {6}, pages = {882.e1-882.e7}, year = {2022} }
RIS	TY - JOUR AU - Salehi M AU - Hosseini H AU - Jamshidi HR AU - Jalili H AU - Tabarsi P AU - Mohraz M AU - Karimi H AU - Lotfinia M AU - Aalizadeh R AU - Mohammadi M AU - Ramazi S AU - Abdoli A TI - Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern JO - Clinical Microbiology and Infection VL - 28 IS - 6 SP - 882.e1 EP - 882.e7 PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract